Education
About Us
Working with TipRanks
Follow Us
Silexion Therapeutics (SLXN)
NASDAQ:SLXN
Total Valuation
Silexion Therapeutics has a market cap or net worth of $5.72M. The enterprise value is -$7.73M.
Market Cap$5.72M
Enterprise Value-$7.73M
Share Statistics
Silexion Therapeutics has 3,126,642 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,126,642
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Silexion Therapeutics’s return on equity (ROE) is 4.12 and return on invested capital (ROIC) is -2504.18%.
Return on Equity (ROE)4.12
Return on Assets (ROA)-5.74
Return on Invested Capital (ROIC)-2504.18%
Return on Capital Employed (ROCE)19.05
Revenue Per Employee0.00
Profits Per Employee-1.50M
Employee Count11
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Silexion Therapeutics is ―. Silexion Therapeutics’s PEG ratio is 0.28.
PE Ratio―
PS Ratio0.00
PB Ratio-47.15
Price to Fair Value-47.15
Price to FCF-22.34
Price to Operating Cash Flow-0.19
PEG Ratio0.28
Income Statement
In the last 12 months, Silexion Therapeutics had revenue of 0.00 and earned -16.44M in profits. Earnings per share was -2.64.
Revenue0.00
Gross Profit0.00
Operating Income-12.57M
Pretax Income-16.51M
Net Income-16.44M
EBITDA-16.48M
Earnings Per Share (EPS)-2.64
Cash Flow
In the last 12 months, operating cash flow was -10.73M and capital expenditures -7.00K, giving a free cash flow of -10.74M billion.
Operating Cash Flow-10.73M
Free Cash Flow-10.74M
Free Cash Flow per Share-3.43
Dividends & Yields
Silexion Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.32
52-Week Price Change-92.23%
50-Day Moving Average2.38
200-Day Moving Average7.38
Relative Strength Index (RSI)35.92
Average Volume (3m)50.14K
Important Dates
Silexion Therapeutics upcoming earnings date is Mar 24, 2026, After Close (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 24, 2026
Ex-Dividend Date―
Financial Position
Silexion Therapeutics as a current ratio of 0.64, with Debt / Equity ratio of 6.95%
Current Ratio0.64
Quick Ratio0.64
Debt to Market Cap0.02
Net Debt to EBITDA-0.20
Interest Coverage Ratio-241.75
Taxes
In the past 12 months, Silexion Therapeutics has paid 10.00K in taxes.
Income Tax10.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Silexion Therapeutics EV to EBITDA ratio is -11.62, with an EV/FCF ratio of -22.74.
EV to Sales0.00
EV to EBITDA-11.62
EV to Free Cash Flow-22.74
EV to Operating Cash Flow-22.80
Balance Sheet
Silexion Therapeutics has $9.24M in cash and marketable securities with $485.00K in debt, giving a net cash position of $8.76M billion.
Cash & Marketable Securities$9.24M
Total Debt$485.00K
Net Cash$8.76M
Net Cash Per Share$2.80
Tangible Book Value Per Share-$0.64
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Silexion Therapeutics is $9.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$9.00
Price Target Upside324.53% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast91.47%